News headlines about American Renal Associates (NYSE:ARA) have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. American Renal Associates earned a news impact score of 0.06 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.6659803007001 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news articles that may have impacted Accern’s scoring:
Shares of NYSE:ARA traded down $0.50 on Friday, hitting $17.05. 171,180 shares of the company’s stock were exchanged, compared to its average volume of 249,129. American Renal Associates has a 12 month low of $9.91 and a 12 month high of $24.07. The company has a market cap of $552.14, a price-to-earnings ratio of 27.95, a price-to-earnings-growth ratio of 1.21 and a beta of 1.94. The company has a current ratio of 1.20, a quick ratio of 1.17 and a debt-to-equity ratio of 4.28.
American Renal Associates (NYSE:ARA) last released its earnings results on Tuesday, March 6th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.03. The business had revenue of $194.40 million during the quarter, compared to the consensus estimate of $195.15 million. American Renal Associates had a positive return on equity of 14.51% and a negative net margin of 1.00%. The business’s revenue for the quarter was down 2.5% compared to the same quarter last year. During the same period last year, the company earned $0.26 earnings per share. equities research analysts predict that American Renal Associates will post 0.73 EPS for the current fiscal year.
Several analysts have recently weighed in on ARA shares. SunTrust Banks set a $20.00 target price on American Renal Associates and gave the stock a “buy” rating in a research report on Thursday, December 21st. Zacks Investment Research downgraded American Renal Associates from a “hold” rating to a “sell” rating in a research report on Tuesday, January 23rd. Finally, Leerink Swann downgraded American Renal Associates from an “outperform” rating to a “market perform” rating and lifted their target price for the stock from $17.00 to $27.00 in a research report on Thursday, March 8th.
ILLEGAL ACTIVITY NOTICE: “American Renal Associates (ARA) Earns News Sentiment Score of 0.06” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.dispatchtribunal.com/2018/04/07/american-renal-associates-ara-earns-news-sentiment-score-of-0-06.html.
American Renal Associates Company Profile
American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.
Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.